Adrenoceptors in Raynaud's disease

Area of Science:

• Physiology
• Pharmacology
• Vascular Biology

Background:

• Raynaud's disease involves exaggerated vasoconstriction.
• Adrenoceptor dysfunction is a potential underlying mechanism.
• Understanding adrenoceptor roles is crucial for Raynaud's disease.

Purpose of the Study:

• To investigate adrenoceptor function in the finger skin of Raynaud's disease patients.
• To compare the effects of sympathetic agonists and antagonists on local skin blood flow between Raynaud's patients and healthy controls.
• To identify specific adrenoceptor subtypes involved in Raynaud's pathophysiology.

Main Methods:

• Iontophoresis of sympathetic agonists (norepinephrine, phenylephrine) and antagonists (doxazosin) into finger skin.
• Evaluation of local skin blood flow changes using laser Doppler technique.
• Comparison of responses in 12 women with Raynaud's disease and 12 healthy controls.

Main Results:

• Norepinephrine and B-HT 933 caused similar vasoconstriction in both groups.
• Healthy controls showed consistent vasoconstriction to phenylephrine.
• Raynaud's subjects exhibited weaker vasoconstriction or vasodilation to phenylephrine, particularly at low concentrations.
• Doxazosin blockade of alpha 1-adrenoceptors in controls replicated the Raynaud's response to phenylephrine.
• Beta-adrenoceptor agonists had no effect on finger blood flow in either group.

Conclusions:

• Raynaud's disease is characterized by a functional defect in alpha 1-adrenoceptor-mediated vasoconstriction.
• Alpha 1-adrenoceptor dysfunction contributes to the altered vascular responses observed in Raynaud's disease.
• Targeting alpha 1-adrenoceptor pathways may offer therapeutic potential for Raynaud's disease.